Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Stericycle is a multinational business-to-business services company with a core pu...
Stericycle is a multinational business-to-busin...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company that...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a gl...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
Intellia Therapeutics is a leading genome editing company focused on developing cu...
Intellia Therapeutics is a leading genome editi...
Join the National Investor Network and get the latest information with your interests in mind.